Controversies in radiotherapy for pediatric Hodgkin's lymphoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 9, 2011, Pages 1357-1366

  Wiegner, Ellen A ^a   Donaldson, Sarah S ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

chemotherapy; pediatric Hodgkin's lymphoma; radiotherapy; response adapted therapy; toxicity

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

AGE DISTRIBUTION; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; EXTENDED FIELD RADIOTHERAPY; GONADAL DISEASE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; INVOLVED FIELD RADIOTHERAPY; LOW DRUG DOSE; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REVIEW; RISK REDUCTION; SOCIAL STATUS; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; RISK FACTORS;

EID: 80053061645     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Kaplan HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 78, 553-561 (1962).
2. Donaldson SS, Kaplan HS. Complications of treatment of Hodgkin's disease in children. Cancer Treat. Rep. 66(4), 977-989 (1982). (Pubitemid 12129384)
3. Willman KY, Cox RS, Donaldson SS. Radiation induced height impairment in pediatric Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 28(1), 85-92 (1994). (Pubitemid 24012858)
4. Bhatia S, Robison LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N. Engl. J. Med. 334(12), 745-751 (1996). (Pubitemid 26089355)
5. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin. Radiat. Oncol. 6(3), 225-242 (1996). (Pubitemid 26259879)
6. Chow LM, Nathan PC, Hodgson DC et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J. Clin. Oncol. 24(36), 5735-5741 (2006).
7. DeVita VT Jr, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann. Intern. Med. 92(5), 587-595 (1980).
8. Donaldson S. Pediatric Hodgkin's disease: focus on the future. In: Status of the Curability of Childhood Cancers. Van Eys J, Sullivan MP (Eds).Raven Press, NY, USA (1980).
9. Cleary SF, Link MP, Donaldson SS. Hodgkin's disease in the very young. Int. J. Radiat. Oncol. Biol. Phys. 28(1), 77-83 (1994).
10. Razzouk BI, Gan YJ, Mendonca C et al. Epstein-Barr virus in pediatric Hodgkin disease: age and histiotype are more predictive than geographic region. Med. Pediatr. Oncol. 28(4), 248-254 (1997). (Pubitemid 27123686)
11. Halperin EC, Tarbell NJ, Kun LE (Eds).Pediatric Radiation Oncology. Lippincott Williams & Wilkins, Philadelphia, PA, USA (2005).
12. Chang ET, Zheng T, Weir EG et al. Childhood social environment and Hodgkin's lymphoma: new findings from a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 13(8), 1361-1370 (2004). (Pubitemid 39071562)
13. Westergaard T, Melbye M, Pedersen JB, Frisch M, Olsen JH, Andersen PK. Birth order, sibship size and risk of Hodgkin's disease in children and young adults: a population-based study of 31 million person-years. Int. J. Cancer 72(6), 977-981 (1997). (Pubitemid 27433561)
14. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J. Clin. Oncol. 7(11), 1630-1636 (1989). (Pubitemid 19272832)
15. Hoppe RTM, Armitage PT, Diehl JO, Weiss LM (Eds).Hodgkin Lymphoma. Lippincott Williams & Wilkins, Philadelphia, PA, USA (2007).
16. Kellenberger CJ, Miller SF, Khan M, Gilday DL, Weitzman S, Babyn PS. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur. Radiol. 14(10), 1829-1841 (2004). (Pubitemid 39386632)
17. Kellenberger CJ, Epelman M, Miller SF, Babyn PS. Fast STIR whole-body MR imaging in children. Radiographics 24(5), 1317-1330 (2004). (Pubitemid 39329377)
18. Hines-Thomas M, Kaste SC, Hudson MM et al. Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with Hodgkin lymphoma. Pediatr. Blood Cancer 51(2), 198-203 (2008). (Pubitemid 351874413)
19. Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am. J. Med. 112(4), 262-268 (2002). (Pubitemid 34219438)
20. Shulkin BL, Goodin GS, McCarville MB et al. Bone and [18F] fluorodeoxyglucose positron-emission tomography/computed tomography scanning for the assessment of osseous involvement in Hodgkin lymphoma in children and young adults. Leuk. Lymphoma 50(11), 1794-1802 (2009).
21. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Harris NL, Jaffe ES et al. (Eds).Lyon, France (2008).
22. Bodis S, Kraus MD, Pinkus G et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J. Clin. Oncol. 15(9), 3060-3066 (1997). (Pubitemid 27377497)
23. Karayalcin G, Behm FG, Gieser PW et al. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment - the Pediatric Oncology Group experience. Med. Pediatr. Oncol. 29(6), 519-525 (1997). (Pubitemid 27419402)
24. Smith RS, Chen Q, Hudson MM et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J. Clin. Oncol. 21(10), 2026-2033 (2003). (Pubitemid 46606393)
25. Dorffel W, Luders H, Ruhl U et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin. Padiatr. 215(3), 139-145 (2003). (Pubitemid 36718285)
26. Ruhl U, Albrecht M, Dieckmann K et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int. J. Radiat. Oncol. Biol. Phys. 51(5), 1209-1218 (2001). (Pubitemid 33116313)
27. Ruhl U AM, Lueders H et al. Abstract at ASTRO, 46th annual meeting: the German Multi-National GPOH-HD 95 trial: treatment results and analysis of failures in pediatric Hodgkins disease using combination chemothreapy with and without radiation. Int. J. Radiat. Oncol. Biol. Phys. 60, S131 (2004).
28. Schwartz CL, Constine LS, Villaluna D et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114(10), 2051-2059 (2009).
29. Hudson MM, Krasin M, Link MP et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J. Clin. Oncol. 22(22), 4541-4550 (2004). (Pubitemid 41185121)
30. Donaldson SS, Link MP, Weinstein HJ et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J. Clin. Oncol. 25(3), 332-337 (2007). (Pubitemid 350003023)
31. Landman-Parker J, Pacquement H, Leblanc T et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J. Clin. Oncol. 18(7), 1500-1507 (2000). (Pubitemid 30205396)
32. Nachman JB, Sposto R, Herzog P et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J. Clin. Oncol. 20(18), 3765-3771 (2002).
33. Kung FH, Schwartz CL, Ferree CR et al. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. J. Pediatr. Hematol. Oncol. 28(6), 362-368 (2006). (Pubitemid 43970392)
34. Tebbi CK, Mendenhall N, London WB, Williams JL, de Alarcon PA, Chauvenet AR. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr. Blood Cancer 46(2), 198-202 (2006) (Pubitemid 43076071)
35. Oberlin O, Leverger G, Pacquement H et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J. Clin. Oncol. 10(10), 1602-1608 (1992). (Pubitemid 23057990)
36. Vecchi V, Pileri S, Burnelli R et al. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer 72(6), 2049-2057 (1993). (Pubitemid 23262142)
37. Salloum E, Doria R, Schubert W et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J. Clin. Oncol. 14(9), 2435-2443 (1996). (Pubitemid 26300109)
38. Koontz BF, Kirkpatrick JP, Clough RW et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J. Clin. Oncol. 24(4), 605-611 (2006). (Pubitemid 46630423)
39. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J. Clin. Oncol. 28(7), 1232-1239 (2010).
40. van den Berg H ZJ, Behrendt H. Treatment of childhood Hodgkin's disease without radiotherapy. Ann. Oncol. 8(Suppl. 1), 15-17 (1997).
41. Mauz-Korholz C, Hasenclever D, Dorffel W et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J. Clin. Oncol. 28(23), 3680-3686 (2010).
42. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25(24), 3746-3752 (2007). (Pubitemid 47372616)
43. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1), 52-59 (2006). (Pubitemid 43053523)
44. Furth C, Steffen IG, Amthauer H et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J. Clin. Oncol. 27(26), 4385-4391 (2009).
45. Pellegrino B, Terrier-Lacombe MJ, Oberlin O et al. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection - a study of the French Society of Pediatric Oncology. J. Clin. Oncol. 21(15), 2948-2952 (2003). (Pubitemid 46621846)
46. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 110(1), 179-185 (2007). (Pubitemid 46986431)
47. Glick JH, Young ML, Harrington D et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J. Clin. Oncol. 16(1), 19-26 (1998). (Pubitemid 28041574)
48. Armata J, Balwierz W, Moryl-Bujakowska A et al. Childhood stage IV Hodgkin disease: therapeutic results of the Polish pediatric leukemia/lymphoma study group. Med. Pediatr. Oncol. 33(4), 382-387 (1999). (Pubitemid 29449349)
49. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J. Clin. Oncol. 20(3), 630-637 (2002). (Pubitemid 34111368)
50. Kelly KM, Sposto R, Hutchinson R et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high risk Hodgkin lymphoma: a report from the Children's Oncology Group CCG-59704 clinical trial. Blood 117(9), 2596-2603 (2010).
51. Weiner MA, Leventhal B, Brecher ML et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J. Clin. Oncol. 15(8), 2769-2779 (1997). (Pubitemid 27330002)
52. Hutchinson RJ, Fryer CJ, Davis PC et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J. Clin. Oncol. 16(3), 897-906 (1998). (Pubitemid 28108721)
53. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother. Oncol. 78(1), 1-5 (2006). (Pubitemid 43131028)
54. Schellong G, Dorffel W, Claviez A et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J. Clin. Oncol. 23(25), 6181-6189 (2005).